Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
All the abstracts at https://academic.oup.com/neuro-oncology/issue/24/Supplement_7
say 'journal article' because, well, those abstracts, dozens and dozens of them, are words written on the journal website... so, 'journal article'. More ammunition for the short sellers... "ahhhh, no journal article ahhwww... crashhh..."
Just click on ANY supplement 7 abstract and you will see the same 'journal article' words.
IMHO
Thanks Stonk, now, if we can get a Booth 214 update... that should have happened by now.
SNO would like to thank its Contributor Level Supporters for the 2022 SNO Annual Meeting and Education Day: @AlexionPharmaUS @EndBrainCancer @Merck @MonterisMed @NorthwestBio Ono Pharma USA, Inc. @plustxinc Pyramid Biosciences & @TGHCares. #SNO2022 pic.twitter.com/mn7d6GH0Jc
— SNO (@NeuroOnc) November 14, 2022
Gary, good thoughts.
I am drinking the Journal before SNO Kool -Aid myself. Otherwise, presenting there makes zero sense.
I think being right behind Dr. Mitchell means something. They have co-authored before.
I like the clinicaltrials.gov est completion date Nov.2022.
I think the INN naming has been an issue and now resolved.
Very very exciting week!!!!
Agreed...and all fingers and toes crossed for it.
dstock, so, the problem with big views and visits is the short sellers. It is them... and not future long shareholders just learning about this company.
My personal experience say this is true.
Before 5/10/22, I posted a video of Dr. Cloughesy saying LL would be presenting TLD ant NYAS. This was viewed 5,000+ time in the 1st 24 hours. The other video's I posted that day, like the one explaining the combo trial, was almost ignored.
That 5,000 view count was way way to high for the few shareholders on ihub and Twitter.... So, it was basically just part of the short sellers gearing up.
This lopsided viewing of LL's abstract page is proof in the pudding they have the same target. NWBO.
Will they succeed ?? I don't know. The bear bait they fell for 5/10/22 may make them weaker and the 10Q warning shot should make them hesitant.
https://twitter.com/EveryTrade/media
all IMHO of course.
I know the 74th INN Executive Summary from June has NWBO wanting canpuldencel. Perhaps that naming was not possible and murcidencel was easier.
More like DCVAX educates your immune system to kill GBM.
I hope for December, but yeah, could be January. Pretty complicated for WHO to hear comments, respond, edit, publish.
If a private joke, it would point to merck or novocure. LOL... instead, looks like a favor to nwbio from a long shareholder.
The INN Summary from October should be out for public viewing in a few weeks/month. In June, canpuldencel-t was attempted. Perhaps murcidencel may have been approved by INN this time?
Anyone can grab and park/forward a domain name. Sometime to protect it incase the company was too busy, or for nefarious reasons.
Now, if they update nwbio.com, that might be something. lol...ok, been fooled on that one too.
oddly, nwbo.com is taken and parked. I think all companies should have their ticker fordaring to their main site.
Thanks, but I'll trust quote from the company versus a midwestern hedgie always attacking the company.
Good Luck on your future ventures.
Fails-to-Deliver is not what was really being discussed, however...
Failure to deliver is critical when discussing naked short selling. When naked short selling occurs, an individual agrees to sell a stock that neither they nor their associated broker possess, and the individual has no way to substantiate their access to such shares. The average individual is incapable of doing this kind of trade. However, an individual working as a proprietary trader for a trading firm and risking their own capital may be able. Though it would be considered illegal to do so, some such individuals or institutions may believe the company they short will go out of business, and thus in a naked short sale they may be able to make a profit with no accountability.
Subsequently, the pending failure to deliver creates what are called "phantom shares" in the marketplace, which may dilute the price of the underlying stock. In other words, the buyer on the other side of such trades may own shares, on paper, which do not actually exist.
They publish 'naked shorts' ??.. huh, I did not know that...Emperor Has No Clothes now !
LP disagrees.
I think they are ANGELS !!
See ya never in 10 years when they have that kind of OS.
Go back to the Yahoo Chat Hole you got kicked out of...
low postings, I think same happened last run-up(s).
I believe it's simply those who want the price suppressed, cannot do it when abstract release tomorrow. It would be a literal waste of their keyboard time. They have to let the price move up some to have a bigger cliff to short it from. IMHO.
Gary, I think you are correct, but not sure on the "all patients" getting dcvax.
I agree 110% that this specific trial is moving the dial. NIH/SPORE... these are real communication pathways to make changes.
Financial was the 1st hold 2012 or 2013, I can't remember.
The temporary screening halt was 2015, which was being discussed.
This is from NWBO PR, "The only change in status of the trial is that new screening of patient candidates for the trial has been temporarily suspended while the Company submits certain information from the trial for regulatory review."
Obviously, the RA's accepted info and NWBO made changes to satisfy.
I am confused by your statements.
"PIII trial is on partial clinical hold for screening of new patients for further enrolment"
"patients already in the trial have continued to be treated in accordance with the trial protocol, without interruption"
"FDA lifts the partial clinical hold on PIII trial."
"There is also some possibility that changes requested by the FDA and/or other regulators could complicate the application process for product approval "
"FDA lifts the partial clinical hold on PIII trial."
"The FDA action clears a regulatory concern for Northwest Bio."
Whatever the reason, game was put back on by the FDA, a long time ago.
Markets Open Friday.
YE=BK...No Adidas, GAP,
Even Madame Tussauds London moved him to the basement.
4 am PST Friday for me. a.k.a. Sleeping.
But the account is still a 'margin account'...so, temporarily freezing so you can't borrow on it won't change that it's still under a 100-page margin agreement(allowing share lending to shorts). LP says they are 100 pages long.
Can you image car and home titles being bought and sold this way... LOL.
The higher the price, the bigger the gap down from short attacks. Short sellers always want the price to go up fast and huge, it is their bread and butter.
NWBO will be volatile for years to come when price moving news finally comes.
Some say "are you ready to get rich on NWBO".. but they never say, 'are you ready to get rich from a long position on NWBO'. IMHO.
Day traders don't own this stock...all day long we hear complaints from super long time shareholders...
The ultra-low volume of 1% float shows that too.
The long-time call-out of .375 when stock was well over $1 and the it bottomed at .39 on 5/10/22.... beyond miraculous with that volume, makers, etc... worthy of a close inspection.
I just believe someone is caught with a hand in the cookie jar and we will find out whom(s) in the next year.
As always, IMHO.
ex, like this ??
I say get more socks.
NYAS also flushed some old stop-loss orders, so, that might neuter the next stop-loss raid. Perhaps that is why I read, and I'm paraphrasing, 'hammer time .50'... That might be the lowest large holder Stop-Loss order in a brokers system.
Well played LP.
I am sure there is an agreement on the P3...just confidential.
Does CRL explain what they will use that capacity for?
Wow, PII trial agreement.. the P3 took 15-20 years, so, you have VERY OLD information.
Document says she is working on behalf of UCLA and that NWBO is to pay UCLA... mind-blowing info.
Huh? UCLA not giving her a paycheck anymore?? Why not??
Not being on BOD keeps her as Non-Paid, to prevent a conflict of interest. LOL
She was paid for being:
1. Editor-in-chief of the Journal of NeuroOncology (2007–2017)
2. Editor "Glioblastoma, Part II: Molecular Targets and Clinical Trials, An Issue of Neurosurgery Clinics of North America" 2021
EXPERT !!! LOL